View Filing Data

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Sep. 30, 2018	Nov. 28, 2018	Mar. 29, 2018
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Entity Registrant Name	Stellar Biotechnologies, Inc.
Entity Central Index Key	0001540159
Current Fiscal Year End Date	--09-30
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Public Float			$ 8,149,918
Trading Symbol	SBOT
Entity Common Stock, Shares Outstanding		5,330,715
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Small Business	true

Consolidated Balance Sheets - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Current assets:
Cash and cash equivalents	$ 4,225,521	$ 4,570,951
Accounts receivable	41,246	1,287
Short-term investments	6,078,031	1,994,401
Inventory	224,267	68,114
Prepaid and other assets	86,919	123,694
Total current assets	10,655,984	6,758,447
Noncurrent assets:
Equity investment in joint venture	46,456	66,695
Property, plant and equipment, net	1,062,195	879,523
Deposits	15,340	15,340
Total noncurrent assets	1,123,991	961,558
Total Assets	11,779,975	7,720,005
Current liabilities:
Accounts payable and accrued liabilities	493,385	320,947
Total Current Liabilities	493,385	320,947
Commitments (Note 7)
Shareholders' equity:
Common shares, unlimited common shares authorized, no par value, 5,330,715 and 1,502,870 issued and outstanding at September 30, 2018 and 2017, respectively	56,652,957	48,351,701
Accumulated share-based compensation	5,064,625	4,439,400
Accumulated deficit	(50,430,992)	(45,392,043)
Total Shareholders' Equity	11,286,590	7,399,058
Total Liabilities and Shareholders' Equity	$ 11,779,975	$ 7,720,005

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2018	Sep. 30, 2017
Common shares, par value	$ 0	$ 0
Common shares, shares issued	5,330,715	1,502,870
Common shares, shares outstanding	5,330,715	1,502,870

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Revenues:
Revenue from Contract with Customer	$ 0	$ 50,000
Total Revenues	211,849	228,287
Expenses:
Cost of sales and contract services	133,316	250,042
Costs of aquaculture	312,004	284,411
Research and development	2,087,402	1,973,400
General and administrative	2,757,377	2,944,980
Total Expenses	5,290,099	5,452,833
Loss from Operations	(5,078,250)	(5,224,546)
Other Income (Loss)
Foreign exchange gain (loss)	(35,059)	162,028
Investment income	75,160	32,670
Other Income (Loss), Total	40,101	194,698
Loss Before Income Tax	(5,038,149)	(5,029,848)
Income tax expense	800	800
Net Loss	$ (5,038,949)	$ (5,030,648)
Loss per common share:
Basic and diluted	$ (1.76)	$ (3.44)
Weighted average number of common shares outstanding:
Basic and diluted	2,869,374	1,462,459
Product [Member]
Revenues:
Revenue from Contract with Customer	$ 211,849	$ 178,287

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Cash Flows Used In Operating Activities:
Net loss	$ (5,038,949)	$ (5,030,648)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	188,372	179,322
Share-based compensation	154,313	115,546
Foreign exchange (gain) loss	35,059	(162,028)
Transfer equipment to research and development	12,419	0
Change in equity investment in joint venture	20,239	0
Changes in working capital items:
Accounts receivable	(40,004)	84,573
Inventory	(156,153)	181,316
Prepaid and other assets	36,748	235,001
Accounts payable and accrued liabilities	172,451	(302,731)
Net cash used in operating activities	(4,615,505)	(4,699,649)
Cash Flows From Investing Activities:
Purchase of property, plant and equipment	(382,810)	(302,733)
Purchase of short-term investments	(9,083,630)	(5,005,607)
Proceeds on sales and maturities of short-term investments	5,000,000	7,000,000
Net cash provided by (used in) investing activities	(4,466,440)	1,691,660
Cash Flows From Financing Activities:
Proceeds from issuance of common shares, net	4,520,319	0
Payments for issuance costs	(398,811)	0
Proceeds from exercise of warrants	4,650,659	0
Net cash provided by financing activities	8,772,167	0
Effect of exchange rate changes on cash and cash equivalents	(35,652)	162,036
Net change in cash and cash equivalents	(345,430)	(2,845,953)
Cash and cash equivalents - beginning of year	4,570,951	7,416,904
Cash and cash equivalents - end of year	4,225,521	4,570,951
Cash (demand deposits)	3,719,041	3,847,655
Cash equivalents	506,480	723,296
Cash and cash equivalents	4,225,521	4,570,951
Supplemental cash flow information:
Cash paid during the period for taxes	800	800
Supplemental disclosure of non-cash transactions:
Issuance costs withheld from escrow proceeds	972,811	0
Fair value of placement agent warrants	$ 470,912	$ 0

Consolidated Statements of Changes in Equity - USD ($)	Total	Common Shares [Member]	Accumulated Share-Based Compensation [Member]	Accumulated Deficit [Member]
Beginning Balance at Sep. 30, 2016	$ 12,314,160	$ 47,280,792	$ 5,394,763	$ (40,361,395)
Beginning Balance (in shares) at Sep. 30, 2016		1,448,036
Issuance of performance shares	0	$ 1,070,909	(1,070,909)	0
Issuance of performance shares (in shares)		54,834
Share-based compensation	115,546	$ 0	115,546	0
Net loss	(5,030,648)	0	0	(5,030,648)
Ending balance at Sep. 30, 2017	7,399,058	$ 48,351,701	4,439,400	(45,392,043)
Ending balance (in shares) at Sep. 30, 2017		1,502,870
Issuance of common shares in equity offering	5,493,130	$ 5,493,130	0	0
Issuance of common shares in equity offering (in shares)		1,388,396
Issuance costs including fair value of placement agent warrants	(1,371,621)	$ (1,842,533)	470,912	0
Issuance of common shares upon exercise of warrants	4,650,659	$ 4,650,659	0	0
Issuance of common shares upon exercise of warrants (in shares)		2,439,449
Share-based compensation	154,313	$ 0	154,313	0
Net loss	(5,038,949)	0	0	(5,038,949)
Ending balance at Sep. 30, 2018	$ 11,286,590	$ 56,652,957	$ 5,064,625	$ (50,430,992)
Ending balance (in shares) at Sep. 30, 2018		5,330,715

Nature of Operations

12 Months Ended

Sep. 30, 2018

Nature of Operations [Abstract]

Nature of Operations [Text Block]

Nature of Operations

Stellar Biotechnologies, Inc. (the Company) is organized under the laws of British Columbia, Canada. The Company’s business is the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). The Company markets and distributes its KLH products to biotechnology and pharmaceutical companies, academic institutions, clinical research organizations and research centers primarily in Europe, North American and Asia. The Company’s common shares have been listed for trading on The Nasdaq Capital Market in the United States under the symbol SBOT since November 5, 2015.

In April 2010, the Company changed its name from CAG Capital, Inc. to Stellar Biotechnologies, Inc. and completed a reverse merger transaction with Stellar Biotechnologies, Inc., a California corporation, which was founded in September 1999, and remains the Company’s wholly-owned subsidiary and principal operating entity. In January 2017, the California subsidiary and the Company established a wholly-owned Mexican subsidiary under the name BioEstelar, S.A. de C.V. in Ensenada, Baja California to perform aquaculture research and development activities in Mexico. The Company’s executive offices are located at 332 E. Scott Street, Port Hueneme, California, 93041, USA, and its registered and records office is 1500 Royal Centre, 1055 West Georgia Street, Vancouver, BC, V6E 4N7, Canada.

Functional Currency

The consolidated financial statements of the Company are presented in U.S. dollars, which is the Company’s functional currency, unless otherwise stated.

Management Plans

Company operations have historically been funded by the issuance of common shares, exercise of warrants, grant revenues, contract services revenue and product sales. For the fiscal years 2018 and 2017, the Company reported net losses of approximately $5.0 million and $5.0 million, respectively. As of September 30, 2018, the Company had an accumulated deficit of approximately $50.4 million and working capital of approximately $10.2 million. The Company expects to incur additional losses as it continues to invest in its research and development programs, manufacturing platform and market development activities.

The Company plans to finance company operations over the course of at least the next twelve months with cash and investments on hand and product sales. Management has flexibility to adjust planned expenditures based on a number of factors including the size and timing of capital expenditures, staffing levels, inventory levels, and the status of customer clinical trials. Management also seeks to expand the customer base for existing marketed products, and may seek additional financing through debt and/or equity financings, including transactions with strategic customers and partners that may include debt and/or equity arrangements. The Company has historically relied upon the sale of common shares to help fund its operations and meet its obligations and presently expects to continue to do so in the future as and when it considers appropriate, subject to market conditions and the availability of favorable terms.

Basis of Presentation

12 Months Ended

Sep. 30, 2018

Basis of Presentation [Abstract]

Basis of Accounting [Text Block]

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and include the accounts of the Company, its wholly-owned subsidiaries, Stellar Biotechnologies, Inc., a California corporation in the U.S. and BioEstelar, S.A. de C.V. a Baja California corporation in Mexico. All significant intercompany balances and transactions have been eliminated in consolidation.

Significant Accounting Policies

12 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reported periods. These estimates include warrant liabilities, share-based compensation, intangible assets, valuation of accounts receivable, valuation of inventory, and income taxes. Actual outcomes could differ from these estimates. These consolidated financial statements include estimates, which by their nature are uncertain. The impacts of such estimates are pervasive throughout the consolidated financial statements, and may require accounting adjustments based on future periods if the revision affects both current and future periods. These estimates are based on historical experience, current and future economic conditions and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Cash and Cash Equivalents

Cash and cash equivalents consist of demand deposits with financial institutions and highly liquid investments which are readily convertible into cash with maturities of three months or less when purchased.

Investments

Investments at September 30, 2018 and 2017 consisted of U.S. Treasury bills with original maturities between 13 and 52 weeks. They are classified as held-to-maturity and are reported at amortized cost, which approximates fair value. The Company regularly reviews these investments to determine whether any decline in fair value below the amortized cost basis has occurred that is other than temporary. If a decline in fair value has occurred that is determined to be other than temporary, the cost basis of the investment is written down to fair value.

Allowance for Doubtful Accounts Receivable

The Company assesses the collectability of its accounts receivable through a review of its current aging, as well as an analysis of its historical collection rate, general economic conditions and credit status of its customers. As of September 30, 2018 and 2017, all outstanding accounts receivable were deemed to be fully collectible, and therefore, no allowance for doubtful accounts was recorded.

Inventory

The Company records inventory at the lower of cost or market, with market not in excess of net realizable value. Raw materials are measured using FIFO (first-in first-out) cost. Work in process and finished goods are measured using average cost.

Property, Plant and Equipment

Property, plant and equipment are recorded at cost less accumulated depreciation and accumulated impairment losses, if any. Depreciation is recorded on the straight-line method over useful lives ranging from 1.5 to 15 years. Leasehold improvements are depreciated over the shorter of the useful life of the improvement or remaining term of lease. Maintenance and repairs are charged to operations as incurred.

Impairment of Long-Lived Assets

If indicators of impairment exist, the Company assesses the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, the amount of such impairment is measured by comparing the carrying value of the asset to the fair value of the asset and the Company records the impairment as a reduction in the carrying value of the related asset and a charge to operating results. Estimating the undiscounted future cash flows associated with long-lived assets requires judgment, and assumptions could differ materially from actual results.

Fair Value of Financial Instruments

The Company uses the fair value measurement framework for valuing financial assets and liabilities measured on a recurring basis in situations where other accounting pronouncements either permit or require fair value measurements. See Note 10 for fair value measurements.

Revenue Recognition

Product Sales

The Company recognizes product sales when KLH product is shipped (for which the risk is typically transferred upon delivery to the shipping carrier) and there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collectability is reasonably assured. The Company documents arrangements with customers with purchase orders and sales agreements.

Product sales include sales made under supply agreements with customers for a fixed price per gram of KLH products based on quantities ordered. Supply agreements are typically on a non-exclusive basis except within that customer’s field of use.

Contract services revenue

The Company recognizes contract services revenue when contract services have been performed and reasonable assurance exists regarding measurement and collectability. An appropriate amount will be recognized as revenue in the period that the Company is assured of fulfilling the contract requirements. Amounts received in advance of performance of contract services are recorded as deferred revenue.

Contract services include services performed under a technology transfer and purchase

agreement.

Research and Development

Research and development expenses principally consist of personnel costs related to the Company’s research and development staff as well as depreciation of research and development assets. Research and development expenses also include costs incurred for laboratory supplies,

KLH designated for internal research use only,

reimbursable costs associated with collaborative agreements, third-party contract payments, consultants, facility and related overhead costs.

Research and development costs are expensed as incurred.

Share-Based Compensation

The Company grants options to buy common shares of the Company to its directors, officers, employees and consultants, and grants other equity-based instruments to non-employees.

The fair value of share-based compensation is measured on the date of grant, using the Black-Scholes option valuation model and is recognized over the vesting period net of estimated forfeitures for employees or the service period for non-employees. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option.

Foreign Exchange

Items included in the financial statements of the Company’s subsidiaries are measured using the currency of the primary economic environment in which the entity operates (the functional currency). The functional currency of the parent and its subsidiaries is the U.S. dollar.

Transactions in currencies other than the U.S. dollar are recorded at exchange rates prevailing on the dates of the transactions.

Income Taxes

Income tax expense comprises current and deferred tax. Income tax is recognized in income or loss except to the extent that it relates to items recognized directly in equity. Current tax expense is the expected tax payable on taxable income for the year, using tax rates enacted or substantively enacted at year-end, adjusted for amendments to tax payable with regards to previous years.

Deferred tax is recorded using the liability method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Temporary differences are not provided for relating to goodwill not deductible for tax purposes. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the balance sheet date.

A deferred tax asset is recognized only to the extent that it is more likely than not that future taxable profits will be available against which the asset can be utilized. To the extent that the Company does not consider it more likely than not that a deferred tax asset will be recovered, it provides a valuation allowance against that excess.

The Company periodically evaluates its tax positions to determine whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authorities. The Company has not incurred any interest or penalties as of September 30, 2018 with respect to uncertain income tax matters. The Company does not expect that there will be unrecognized tax benefits of a significant nature that will increase or decrease within 12 months of the reporting date.

The Company files income tax returns in the U.S. federal and state jurisdictions and in Canada on a fiscal year basis. Mexico tax returns are on a calendar year basis. Management believes that there are no material uncertain tax positions that would impact the accompanying consolidated financial statements. The Company's policy is to recognize interest and penalties related to unrecognized tax benefits in income tax expense.

The Company may be subject to examination by the Internal Revenue Service for tax years 2014 through 2017 and by the Canada Revenue Agency for tax years 2014 through 2018. The Company may also be subject to examination on certain state, local and other foreign jurisdictions for the tax years 2013 through 2018.

Earnings (Loss) Per Share

Basic earnings (loss) per share is calculated by dividing income available to common shareholders by the weighted average number of common shares outstanding during the period.

The computation of diluted earnings (loss) per share assumes the conversion, exercise or contingent issuance of securities only when such conversion, exercise or issuance would have a dilutive effect on earnings (loss) per share. The dilutive effect of convertible securities is reflected in diluted earnings per share by application of the “if converted” method. The dilutive effect of outstanding options and warrants and their equivalents is reflected in diluted earnings per share by application of the treasury stock method. Conversion of outstanding warrants, broker units and options would have an antidilutive effect on loss per share for the years ended September 30, 2018 and 2017 and are therefore excluded from the computation of diluted loss per share.

Segments

The Company operates in one reportable segment and, accordingly, no segment disclosures have been presented. All equipment, leasehold improvements and other fixed assets owned by the Company are physically located within the United States (except for insignificant leasehold improvements under evaluation in Baja California, Mexico), and all supply, collaboration and licensing agreements are denominated in U.S. dollars.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (FASB) issued guidance codified in Accounting Standards Codification (ASC) 606

Revenue Recognition – Revenue from Contracts with Customers

. The standard, including subsequently issued amendments, will replace most existing revenue recognition guidance and industry-specific guidance when it becomes effective. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity applies a five-step approach outlined in the standard. We plan to adopt ASC 606 using the modified retrospective method at the effective date for the Company, during the first quarter of fiscal 2019.

Management has completed a review of existing revenue arrangements following the five-step approach. No material differences have been identified that impact the amount or timing of product sales or contract services revenue between the new revenue recognition guidance as compared to the current guidance. The Company continues to assess disclosures required by the new guidance to determine what additional information will be disclosed.

In January 2016, the FASB issued ASU 2016-01,

Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities

, which primarily affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, ASU 2016-01 clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The guidance is effective for public entities for fiscal years beginning after December 15, 2017, including interim periods within those years, with early adoption permitted. These standards are effective for the Company during the fiscal year ending September 30, 2019. Management believes ASU 2016-01 will not have a significant impact on the Company’s consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02,

Leases (Topic 842)

, which establishes a new lease accounting model for lessees. The updated guidance, including subsequently issued amendments, requires an entity to recognize assets and liabilities on the balance sheet arising from a lease for both financing and operating leases, along with additional qualitative and quantitative disclosures. The amended guidance is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within those years, with early adoption permitted. These standards are effective for the Company during the fiscal year ending September 30, 2020. We anticipate adoption of ASU 2016-02, will result in lease liabilities and right-of-use assets on the Company’s consolidated financial statements for three operating leases with terms ending in July 2020, October 2020 and November 2020. Management will continue to assess the impact of ASU 2016-02 on the Company’s consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13,

Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments

, which includes provisions that require financial assets measured at amortized cost basis to be presented at the net amount expected to be collected and credit losses relating to available-for-sale debt securities to be recorded through an allowance for credit losses, which requires recognition of an estimate of all current expected credit losses. The guidance is effective for public entities for fiscal years beginning after December 15, 2019, including interim periods within those years, with early adoption permitted for fiscal years beginning after December 15, 2018. These standards are effective for the Company during the fiscal year ending September 30, 2021. Management is in the process of assessing the impact of ASU 2016-13 on the Company’s consolidated financial statements.

In May 2017, the FASB issued ASU 2017-09,

Scope of Modification Accounting

, which provides new guidance on changes to the terms or conditions of share-based payment awards that would be required to apply modification accounting under ASC 718,

Compensation-Stock Compensation

. The amendments are effective for annual reporting periods beginning after December 15, 2017 with early adoption permitted. These standards are effective for the Company during the fiscal year ending September 30, 2019. Management believes ASU 2017-09 will not have a significant impact on the Company's consolidated financial statements.

Investments

12 Months Ended

Sep. 30, 2018

Investments, Debt and Equity Securities [Abstract]

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

Investments

Short-term investments consisted of the following:

	September 30,		September 30,
	2018		2017

U.S. Treasury Bills	$	6,078,031	$	1,994,401

U.S. Treasury Bills are carried at amortized cost which approximates fair value and are classified as held-to-maturity investments.

Inventory

12 Months Ended

Sep. 30, 2018

Inventory [Abstract]

Inventory Disclosure [Text Block]

Inventory

Raw materials include inventory of manufacturing supplies. Work in process includes manufacturing supplies, direct and indirect labor, contracted manufacturing and testing, and allocated manufacturing overhead for inventory in process at the end of the year. Finished goods include products that are complete and available for sale. At September 30, 2018 and 2017, the Company recorded work in process and finished goods inventory only for those products with recent sales levels to evaluate net realizable value.

Inventory consisted of the following:

	September 30,		September 30,
	2018		2017

Raw materials	$	46,670	$	21,761
Work in process		83,297		-
Finished goods		94,300		46,353

	$	224,267	$	68,114

Property, Plant and Equipment, net

12 Months Ended

Sep. 30, 2018

Property, Plant and Equipment, net [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

Property, Plant and Equipment, net

Property, plant and equipment, net consisted of the following:

	September 30,			September 30,
	2018			2017

Aquaculture system	$	126,257		$	126,257
Laboratory facilities		62,033			62,033
Computer and office equipment		125,859			117,840
Manufacturing and laboratory equipment		1,042,993			982,439
Vehicles		77,994			77,994
Leasehold improvements		347,360			337,060
		1,782,496			1,703,623
Less: accumulated depreciation		(1,146,566	)		(969,418	)

Depreciable assets, net		635,930			734,205
Construction in progress		426,265			145,318

	$	1,062,195		$	879,523

Depreciation expense amounted to approximately $188,000 and $179,000 for the years ended September 30, 2018 and 2017, respectively.

Commitments

12 Months Ended

Sep. 30, 2018

Commitments [Abstract]

Commitments and Contingencies Disclosure [Text Block]

Commitments

Operating leases

The Company leases buildings and facilities used in its operations under two sublease agreements. In June 2015, the Company exercised its option to extend these sublease agreements for an additional five-year term beginning in October and November 2015. The Company negotiated an option to extend the leases for two additional five-year terms.

The Company leases facilities used for executive offices and laboratories and pays a portion of the common area maintenance. In July 2018, the Company extended this lease for a two-year term, with options to renew for three successive two-year terms.

The Company leases undeveloped land in Baja California, Mexico to assess the potential development of an additional aquaculture locale and expansion of production. The lease term was three years from June 2015 with options to extend the lease for 30 years. In February 2018, the lease term was extended for two years without further rent payments. The Company may terminate early with 30 days’ notice. The Company had a related collaboration agreement with the lessor, which expired in June 2018, pursuant to which the Company and the lessor would collaborate on the design, expansion and development of marine aquaculture resources and KLH production facilities on the leased property. Under that agreement, the Company was responsible for certain leasehold improvements including construction of structures and a power-generating facility, which are owned by the Company. The Company was also responsible for reimbursing the lessor for local operational support.

Aggregate future minimum lease payments at September 30, 2018 are approximately as follows:

For The Year Ending September 30,
2019	$	185,000
2020		167,000
2021		6,000

	$	358,000

Rent expense on these lease agreements amounted to approximately $237,000 and $238,000 for the years ended September 30, 2018 and 2017, respectively.

Purchase obligations

The Company has commitments totaling approximately $201,000 at September 30, 2018, for signed agreements with contract research organizations, consultants and construction contractors.

Supply agreements

The Company has commitments under supply agreements with customers for fixed prices per gram of KLH in connection with clinical trials on a non-exclusive basis except within that customer’s field of use. The expiration dates of these supply agreements range from October 2019 to February 2022, and are generally renewable upon written request of the customer.

Joint venture agreement

In May 2016, the Company entered into a joint venture agreement with another party for the formation of a joint venture company to manufacture and sell conjugated therapeutic vaccines. The joint venture is organized as a French simplified corporation.

The Company holds a 30% equity interest in the joint venture in exchange for an initial capital contribution of €120,000. One-half of the initial contribution, approximately $67,000, was paid during the year ended September 30, 2016 with the balance due upon the occurrence of certain defined future events. The Company will also provide the joint venture additional financing as may be required, on a pro rata basis in line with our equity interest. According to the joint venture agreement, as amended February 2018, if certain milestones are not achieved by December 31, 2018, the joint venture will be dissolved, unless (i) the parties mutually agree to pursue the joint venture arrangement, or (ii) either party decides to purchase the equity interests of the other party. Each of the parties is entitled, upon the occurrence of certain defined events, to acquire the interest of the other party. Except as described herein, the joint venture has an initial ten-year term, renewable for successive five-year terms. If either party provides notice at least six months prior to the expiration date of an applicable term that it does not wish to continue its participation in the joint venture, the other party will have a right to acquire all of such terminating party’s equity interests in the joint venture.

Licensing agreement and technology transfer agreement

In July 2013, the Company acquired the exclusive, worldwide license to certain patented technology for the development of human immunotherapies against

Clostridium difficile

infection (C. diff) under a written agreement (the License Agreement) with a University (the Licensor) which required payments of license fees, patent cost reimbursements and other contingent fees. In March 2017, (i) the Company entered into an agreement to terminate the License Agreement, (ii) the Company concurrently entered into a technology transfer and purchase agreement (the Transfer Agreement) with a vaccine biotechnology company (the Transferee), and (iii) the Licensor and Transferee entered into a direct licensing arrangement relating to the patented C. diff technology. Under the Transfer Agreement, the Company transferred to the Transferee its proprietary rights and know-how of immunogens and vaccine technology for C. diff, in exchange for an upfront payment and a percentage of future fees, milestone payments, sublicensing income and royalties, if any, paid by the Transferee or its assigns to the Licensor.

As a result of the termination of the License Agreement, there are no early termination penalties and no further annual licensing fees, contingent milestone payments, royalties, sub-licensing fees or other financial obligations payable by the Company to the Licensor.

Retirement savings plan 401(k) contributions

The Company sponsors a 401(k) retirement savings plan that requires an annual non-elective safe harbor employer contribution of 3% of eligible employee wages. All employees over 21 years of age are eligible beginning the first payroll after 3 consecutive months of employment. Employees are 100% vested in employer contributions and in any voluntary employee contributions. Contributions to the 401(k) plan were approximately $75,000 and $62,000 for the years ended September 30, 2018 and 2017, respectively.

Related party commitments:

Patent

oyalty agreement

On August 14, 2002, through its California subsidiary, the Company entered into an agreement with a director and officer of the Company, where he would receive royalty payments in exchange for assignment of his patent rights to the Company. The royalty is 5% of gross receipts from products using this invention in excess of $500,000 annually. The Company’s current operations utilize this invention. There was no royalty expense incurred during the years ended September 30, 2018 and 2017.

Share Capital

12 Months Ended

Sep. 30, 2018

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

Share Capital

The Company had the following transactions in share capital:

	Years Ended
	September 30,			September 30,
	2018			2017

Number of common shares issued		3,827,845			54,834

Issuance of common shares	$	5,493,130		$	-
Issuance of common shares upon exercise of warrants		4,650,659			-
Issuance of performance shares		-			1,070,909

Share issuance costs		(1,371,621	)
Fair value of placement agent warrants		(470,912	)

Equity Offerings

On May 15, 2018, the Company completed a registered public offering of 1,388,396 units, with each unit consisting of (i) one common share, no par value, or common share equivalent, and (ii) one warrant to purchase one common share at a price of $2.65 per

unit. The registered public offering also included 687,076 pre-funded units, offered to certain purchasers in lieu of units that would otherwise result in such purchaser’s beneficial ownership exceeding 4.99% (or at the election of a purchaser, 9.99%) of outstanding common shares. The purchase price of each pre-funded unit was equal to the price per unit being sold to the public, minus $0.01, and the exercise price of each pre-funded warrant included in the pre-funded unit was $0.01 per common share. Net proceeds

were $4.6 million, after deducting underwriting discounts and commissions and estimated offering expenses. The warrants were immediately exercisable at an aggregate price of $2.65 and expire five years from the date of issuance. In connection with the offering, the Company also issued warrants to purchase an aggregate of 145,283 common shares, at an exercise price of $3.3125, to certain affiliated designees of the placement agent as part of the placement agent’s compensation.

On May 24, 2018, the Company entered into a warrant exercise agreement with certain holders of our warrants, pursuant to which the holders agreed to exercise their warrants to purchase 1,122,076 common shares, in the aggregate, resulting in net proceeds of $2.5 million. In consideration, the Company agreed to issue to the holders new Series A Common Share Purchase Warrants to purchase up to 1,122,076 common shares at an exercise price of $2.65 per share, with an exercise period of five years, and new Series B Common Share Purchase Warrants to purchase up to 2,244,152 common shares at an exercise price of $2.65 per share, with an exercise period of seven months. In connection with the agreement, the Company also issued warrants to purchase an aggregate of 78,545 common shares to certain affiliated designees of the placement agent as part of the placement agent’s compensation, at an exercise price of $3.3125.

Reverse Share Split

On May 4, 2018, the Company effected a share consolidation (reverse split) of the Company's common shares at a ratio of 1-for-7. As a result of the reverse split, every seven shares of the issued and outstanding common shares, without par value, consolidated into one newly-issued outstanding common share, without par value. Each fractional share remaining after the reverse split that was less than one-half of a share was cancelled and each fractional share that was at least one-half of a share was changed to one whole share. The reverse split reduced the number of common shares outstanding from 10,520,096 to 1,502,870 after fractional share rounding. The number of warrants and options were proportionately adjusted by the split ratio and the exercise prices correspondingly increased by the same split ratio. All shares and exercise prices are presented on a post-split basis in these consolidated financial statements.

Performance Shares

Pursuant to a performance share plan approved by shareholders in 2010, 142,857 common shares were reserved for issuance to certain officers, directors and employees of the Company upon achievement of certain milestones related to completion of method development for commercial-scale manufacture of KLH, compilation and regulatory submittal of all required chemistry, manufacturing and control data and completion of preclinical toxicity and immunogenicity testing of products. Share-based compensation was recorded over the estimated vesting period ending in August 2012.

At September 30, 2017, all vested performance shares under the plan had been issued, and the performance share plan was terminated.

Black-Scholes option valuation model

The Company uses the Black-Scholes option valuation model to determine the fair value of warrants, broker units and share options. Option valuation models require the input of highly subjective assumptions including the expected price volatility. The Company has used historical volatility to estimate the volatility of the share price. Changes in the subjective input assumptions can materially affect the fair value estimates, and therefore the existing models do not necessarily provide a reliable single measure of the fair value of the Company’s warrants, broker units and share options.

Warrants

A summary of the Company’s warrants activity is as follows:

	Number of Warrants			Weighted Average Exercise Price

Balance - September 30, 2017		180,805		$	31.50

Granted		5,665,528			2.68
Granted pre-funded warrants		687,076			.01
Exercised		(1,752,373	)		2.65
Exercised pre-funded warrants		(687,076	)		.01

Balance - September 30, 2018		4,093,960		$	3.96

The weighted average contractual life remaining on the outstanding warrants at September 30, 2018 is 28 months.

The following table summarizes information about the warrants outstanding at September 30, 2018:

Exercise Price		Number of Warrants		Expiry Date

$	2.65		2,044,152	December 2018
	31.50		180,805	January 2022
	2.65		1,645,175	May 2023
	3.31		223,828	May 2023

			4,093,960

The fair value of placement agent warrants granted was determined using the Black-Scholes option valuation model, using the following weighted average assumptions at the date of the grant:

	Year Ended
	September 30,
	2018
Risk free interest rate		2.21	%
Expected life (years)		5.0
Expected share price volatility		173	%
Expected dividend yield		0	%

The weighted average fair value of placement agent warrants granted during the year ended September 30, 2018 was $1.98.

Share Options

The Company adopted an incentive compensation plan in 2017 (the Incentive Plan), which amended and restated the 2013 fixed share option plan and is administered by the Board of Directors. Options, restricted shares and restricted share units are eligible for grants under the Incentive Plan. The number of shares available for issuance under the Incentive Plan is 228,143, including shares available for the exercise of outstanding options under the 2013 fixed share option plan. No restricted shares or restricted share units have been granted as of September 30, 2018.

The exercise price of an option is set at the closing price of the Company’s common shares on the date of grant. Share options granted to directors, officers, employees and certain individual consultants for past service are subject to the following vesting schedule: (a) one-third shall vest immediately, (b) one-third shall vest at 12 months from the date of grant and (c) one-third shall vest at 18 months from the date of grant.

Share options granted to directors, officers, employees and certain individual consultants for future service are subject to the following vesting schedule: (x) one-third shall vest at 12 months from the date of grant, (y) one-third shall vest at 24 months from the date of grant and (z) one-third shall vest at 36 months from the date of grant.

Share options granted to certain individual investor relations consultants are subject to the following vesting schedule: (aa) 25% shall vest at 3 months from the date of grant, (bb) 25% shall vest at 6 months from the date of grant, (cc) 25% shall vest at 12 months from the date of grant and (dd) 25% shall vest at 15 months from the date of grant.

Options have been granted under the Incentive Plan allowing the holders to purchase common shares of the Company as follows:

	Number of Options			Weighted Average Exercise Price

Balance - September 30, 2017		58,711		$	40.18

Granted		29,426			5.88
Expired		(2,266	)		84.87
Expired		(15,373	)		42.07	CDN $

Balance - September 30, 2018		70,498		$	25.42

The weighted average contractual life remaining on the outstanding options is 49 months.

The following table summarizes information about the options under the Incentive Plan outstanding and exercisable at September 30, 2018:

Number of Options		Exercisable at September 30, 2018		Range of exercise prices	Expiry Dates
	13,479		13,479	CDN$15.00 - 35.00	Apr 2019 - Dec 2019
	40,046		17,326	$5.00 - 20.00	Sep 2023 - Mar 2025
	7,571		7,571	CDN$40.00 - 70.00	May 2020 - Jun 2022
	2,114		2,114	$50.00 - 60.00	Dec 2022
	3,073		3,073	CDN$105.00 - 140.00	Nov 2018 - Nov 2021
	4,215		4,215	$120.00 - 130.00	Nov 2020
	70,498		47,778

The estimated fair value of the share options granted was determined using a Black-Scholes option valuation model with the following weighted average assumptions:

	Years Ended
	September 30,			September 30,
	2018			2017
Risk free interest rate		2.13	%		1.44	%
Expected life (years)		7.00			7.00
Expected share price volatility		155	%		166	%
Expected dividend yield		0	%		0	%

The weighted average fair value of share options granted during the years ended September 30, 2018 and 2017 was $5.67, and $12.88, respectively.

As of September 30, 2018, the Company had approximately $72,000 of unrecognized share-based compensation expense, which is expected to be recognized over a period of 28 months.

There were no options exercised during the years ended September 30, 2018 and 2017. There was no intrinsic value of the vested options at September 30, 2018.

Income Taxes

12 Months Ended

Sep. 30, 2018

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

Income Taxes

The breakdown of loss before income tax by jurisdiction is as follows:

	Years Ended
	September 30,			September 30,
	2018			2017

U.S.	$	(4,306,650	)	$	(4,540,094	)
Canadian		(623,835	)		(464,990	)
Other foreign		(107,664	)		(24,764	)

Total Loss Before Income Tax	$	(5,038,149	)	$	(5,029,848	)

Deferred income tax assets and liabilities of the Company are as follows:

	September 30, 2018			September 30, 2017

Deferred income tax assets:
Non-capital loss carry-forwards	$	10,646,900		$	12,164,100
Research and development tax credits		1,117,100			947,300
Deferred expenses		36,400			34,300
Property, plant and equipment		-			2,200
Share issuance costs		981,800			142,600
Deferred income tax liabilities:
U.S. federal benefit (liability) of state deferred taxes		(666,700	)		(923,700	)
Property, plant and equipment		(1,800	)		-
Valuation allowance		(12,113,700	)		(12,366,800	)

Net deferred income tax asset (liability)	$	-		$	-

Realization of the deferred tax assets is dependent upon the generation of future taxable income, the amount and timing of which are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance.

As of September 30, 2018, the Company had federal net operating loss (NOL) carryforwards of approximately $29.6 million expiring 2030 through 2038, California NOL carryforwards of approximately $29.2 million expiring 2030 through 2038, and Canadian federal and provincial NOL carryforwards of approximately CDN$8.7 million expiring 2028 through 2038. Portions of these NOL carryforwards may be used to offset future taxable income, if any.

As of September 30, 2018, the Company also has federal and California research and development tax credit carryforwards of approximately $0.53 million and $0.58 million, respectively, available to offset future taxes. The federal credits begin expiring in 2028 and continue expiring through 2038. The state tax credits do not expire.

Under the provisions of Section 382 of the Internal Revenue Code, substantial changes in the Company's ownership limit the amount of net operating loss carryforwards and tax credit carryforwards that can be utilized annually in the future to offset taxable income. A valuation allowance has been established to reserve the potential benefits of these carryforwards in the Company's consolidated financial statements to reflect the uncertainty of future taxable income required to utilize available tax loss carryforwards and other deferred tax assets.

The income tax expense shown in the consolidated statements of operations differs from the amounts obtained by applying statutory rates to the loss before provision for income taxes due to the following:

	Years Ende d
	September 30, 2018			September 30, 2017

Combined Canadian federal and provincial tax rates		27.0	%		26.0	%

Expected income tax (recovery)/expense	$	(1,360,300	)	$	(1,307,800	)

Nondeductible share-based payments		41,700			30,000
Deductible share issuance costs		(287,300	)		(66,300	)
Effect of income tax rate differences in the U.S. and Mexico		(33,500	)		(624,400	)
Impact of tax rate changes		2,906,100			-
Foreign currency differences		9,500			(42,200	)
Other		(143,100	)		(108,200	)
Change in valuation allowance on deferred tax assets		(1,132,300	)		2,119,700

Income tax expense	$	800		$	800

On December 22, 2017, the Tax Cuts and Jobs Act (the Tax Act) was enacted into law in the U.S. The Tax Act contains a broad range of tax reform measures, including a reduction in the U.S. federal corporate tax rate from 35% to 21% effective January 1, 2018. The Company remeasured certain tax assets and liabilities at September 30, 2018 based on expected lower future U.S. federal tax rates expected to apply when temporary differences reverse in the future. SEC Staff Accounting Bulletin No. 118, “Income Tax Accounting Implications of the Tax Cuts and Jobs Act” (SAB 118), allows provisional amounts to be recorded for the tax effects of the Tax Act when the necessary information is not available, prepared, or analyzed in reasonable detail to finalize its accounting for the changes in the tax law during a measurement period not to extend beyond one year of the enactment date. The Company has provisionally recorded a $2.95 million reduction of deferred tax assets with a corresponding reduction in the valuation allowance for our U.S. subsidiary. Certain aspects of the Tax Act are still being analyzed which could potentially affect the measurement of these balances or potentially give rise to new deferred tax amounts. Potential adjustments are not expected to have a material impact since any adjustments would be fully offset by a valuation allowance. The Company expects to finalize its analysis within the measurement period in accordance with SAB 118 after completing reviews of additional guidance issued by the Internal Revenue Service.

On November 2, 2017, Bill 2-2017, Budget Measures Implementation Act (the Budget Act) came into force in British Columbia, increasing the provincial corporate tax rate from 11% to 12% effective January 1, 2018. The Company remeasured certain tax assets and liabilities at September 30, 2018 based on the provincial tax rates expected to apply when temporary differences reverse in the future. The Company has recorded a $0.04 million increase in deferred tax assets with a corresponding increase in the valuation allowance.

The components of income tax provision (benefits) are as follows:

	Years Ended
	September 30, 2018			September 30, 2017

Current tax provision
U.S. federal	$	-		$	-
Canadian		-			-
Other foreign		-			-
State		800			800

Deferred tax provision
U.S. federal		2,059,300			(1,447,100	)
Canadian		(446,700	)		(199,100	)
Other foreign		(22,600	)		(5,200	)
State		(457,700	)		(468,300	)

Change in valuation allowance on deferred tax assets		(1,132,300	)		2,119,700

Total	$	800		$	800

Fair Value of Financial Instruments

12 Months Ended

Sep. 30, 2018

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

10.

Fair Value of Financial Instruments

Fair value of a financial instrument is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The carrying value of certain financial instruments such as accounts receivable, accounts payable, accrued liabilities, and deferred revenue approximates fair value due to the short-term nature of such instruments. Short-term investments in U.S. Treasury Bills are recorded at amortized cost, which approximates fair value.

The Company follows the fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. There are three levels of inputs that may be used to measure fair value:

	Level 1:	Quoted prices in active markets for identical or similar assets and liabilities.
	Level 2:	Quoted prices for identical or similar assets and liabilities in markets that are not active or observable inputs other than quoted prices in active markets for identical or similar assets and liabilities.
	Level 3:	Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company reports its short-term investments in U.S. Treasury Bills at fair value using Level 1 inputs in the fair value hierarchy.

The following table summarizes fair values for those assets and liabilities with fair value measured on a recurring basis.

	Fair Value Measurements Using
	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Fair Value

September 30, 2018
Assets
Short-term investments in U.S. Treasury Bills	$	6,078,031	$	-	$	-	$	6,078,031

September 30, 2017
Assets
Short-term investments in U.S. Treasury Bills	$	1,994,401	$	-	$	-	$	1,994,401

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Concentrations of Credit Risk

12 Months Ended

Sep. 30, 2018

Concentrations of Credit Risk [Abstract]

Concentration Risk Disclosure [Text Block]

11.

Concentrations of Credit Risk

Credit risk is the risk of an unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations. Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents, U.S Treasury Bills, and accounts receivable. The Company estimates its maximum credit risk at the amount recorded on the balance sheet.

Management’s assessment of the Company’s credit risk for cash and cash equivalents is low as they are held in major financial institutions believed to be credit worthy or U.S. Treasury Bills with maturities of 90 days or less. The Company limits its exposure to credit loss for short-term investments by holding U.S. Treasury Bills with maturities of 1 year or less. Based on credit monitoring and history, the Company considers the risk of credit losses due to customer non-performance on accounts receivable to be low.

The Company had the following concentrations of revenues by customers, each of which accounted for more than 10% of revenues in the applicable period:

	Years Ended
	September 30,		September 30,
	2018		2017
Product sales and contract services revenue		59% from 2 customers		79% from 2 customers

The Company had the following concentrations of revenues by geographic areas:

	Years Ended
	September 30,			September 30,
	2018			2017

Europe		51	%		64	%
North America		45	%		33	%
Asia		4	%		3	%

The Company had the following concentrations of accounts receivable from its customers, each of which accounted for more than 10% in the applicable period:

		September 30,
		2018

Accounts receivable		87% from 2 customers

There were no customer accounts receivable at September 30, 2017.

Significant Accounting Policies (Policies)

12 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

Investment, Policy [Policy Text Block]

Investments

Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]

Allowance for Doubtful Accounts Receivable

Inventory, Policy [Policy Text Block]

Inventory

Property, Plant and Equipment, Policy [Policy Text Block]

Property, Plant and Equipment

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Impairment of Long-Lived Assets

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

Product Sales

Contract services revenue

Contract services include services performed under a technology transfer and purchase

agreement.

Research and Development Expense, Policy [Policy Text Block]

Research and Development

KLH designated for internal research use only,

reimbursable costs associated with collaborative agreements, third-party contract payments, consultants, facility and related overhead costs.

Research and development costs are expensed as incurred.

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Share-Based Compensation

The Company grants options to buy common shares of the Company to its directors, officers, employees and consultants, and grants other equity-based instruments to non-employees.

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Foreign Exchange

Transactions in currencies other than the U.S. dollar are recorded at exchange rates prevailing on the dates of the transactions.

Income Tax, Policy [Policy Text Block]

Income Taxes

Earnings Per Share, Policy [Policy Text Block]

Earnings (Loss) Per Share

Basic earnings (loss) per share is calculated by dividing income available to common shareholders by the weighted average number of common shares outstanding during the period.

Segment Reporting, Policy [Policy Text Block]

Segments

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (FASB) issued guidance codified in Accounting Standards Codification (ASC) 606

Revenue Recognition – Revenue from Contracts with Customers

In January 2016, the FASB issued ASU 2016-01,

Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities

In February 2016, the FASB issued ASU 2016-02,

Leases (Topic 842)

In June 2016, the FASB issued ASU 2016-13,

Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments

In May 2017, the FASB issued ASU 2017-09,

Scope of Modification Accounting

, which provides new guidance on changes to the terms or conditions of share-based payment awards that would be required to apply modification accounting under ASC 718,

Compensation-Stock Compensation

Investments (Tables)

12 Months Ended

Sep. 30, 2018

Investments, Debt and Equity Securities [Abstract]

Schedule Of Short Term Investments [Table Text Block]

Short-term investments consisted of the following:

	September 30,		September 30,
	2018		2017

U.S. Treasury Bills	$	6,078,031	$	1,994,401

Inventory (Tables)

12 Months Ended

Sep. 30, 2018

Inventory [Abstract]

Schedule of Inventory, Current [Table Text Block]

Inventory consisted of the following:

	September 30,		September 30,
	2018		2017

Raw materials	$	46,670	$	21,761
Work in process		83,297		-
Finished goods		94,300		46,353

	$	224,267	$	68,114

Property, Plant and Equipment, net (Tables)

12 Months Ended

Sep. 30, 2018

Property, Plant and Equipment, net [Abstract]

Property, Plant and Equipment [Table Text Block]

Property, plant and equipment, net consisted of the following:

	September 30,			September 30,
	2018			2017

Aquaculture system	$	126,257		$	126,257
Laboratory facilities		62,033			62,033
Computer and office equipment		125,859			117,840
Manufacturing and laboratory equipment		1,042,993			982,439
Vehicles		77,994			77,994
Leasehold improvements		347,360			337,060
		1,782,496			1,703,623
Less: accumulated depreciation		(1,146,566	)		(969,418	)

Depreciable assets, net		635,930			734,205
Construction in progress		426,265			145,318

	$	1,062,195		$	879,523

Commitments (Tables)

12 Months Ended

Sep. 30, 2018

Commitments [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

Aggregate future minimum lease payments at September 30, 2018 are approximately as follows:

For The Year Ending September 30,
2019	$	185,000
2020		167,000
2021		6,000

	$	358,000

Share Capital (Tables)

12 Months Ended

Sep. 30, 2018

Class of Warrant or Right [Line Items]

Schedule of Stockholders Equity [Table Text Block]

The Company had the following transactions in share capital:

	Years Ended
	September 30,			September 30,
	2018			2017

Number of common shares issued		3,827,845			54,834

Issuance of common shares	$	5,493,130		$	-
Issuance of common shares upon exercise of warrants		4,650,659			-
Issuance of performance shares		-			1,070,909

Share issuance costs		(1,371,621	)
Fair value of placement agent warrants		(470,912	)

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

A summary of the Company’s warrants activity is as follows:

	Number of Warrants			Weighted Average Exercise Price

Balance - September 30, 2017		180,805		$	31.50

Granted		5,665,528			2.68
Granted pre-funded warrants		687,076			.01
Exercised		(1,752,373	)		2.65
Exercised pre-funded warrants		(687,076	)		.01

Balance - September 30, 2018		4,093,960		$	3.96

Schedule Of Warrants Outstanding [Table Text Block]

The following table summarizes information about the warrants outstanding at September 30, 2018:

Exercise Price		Number of Warrants		Expiry Date

$	2.65		2,044,152	December 2018
	31.50		180,805	January 2022
	2.65		1,645,175	May 2023
	3.31		223,828	May 2023

			4,093,960

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

Options have been granted under the Incentive Plan allowing the holders to purchase common shares of the Company as follows:

	Number of Options			Weighted Average Exercise Price

Balance - September 30, 2017		58,711		$	40.18

Granted		29,426			5.88
Expired		(2,266	)		84.87
Expired		(15,373	)		42.07	CDN $

Balance - September 30, 2018		70,498		$	25.42

Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]

The following table summarizes information about the options under the Incentive Plan outstanding and exercisable at September 30, 2018:

Number of Options		Exercisable at September 30, 2018		Range of exercise prices	Expiry Dates
	13,479		13,479	CDN$15.00 - 35.00	Apr 2019 - Dec 2019
	40,046		17,326	$5.00 - 20.00	Sep 2023 - Mar 2025
	7,571		7,571	CDN$40.00 - 70.00	May 2020 - Jun 2022
	2,114		2,114	$50.00 - 60.00	Dec 2022
	3,073		3,073	CDN$105.00 - 140.00	Nov 2018 - Nov 2021
	4,215		4,215	$120.00 - 130.00	Nov 2020
	70,498		47,778

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

The estimated fair value of the share options granted was determined using a Black-Scholes option valuation model with the following weighted average assumptions:

	Years Ended
	September 30,			September 30,
	2018			2017
Risk free interest rate		2.13	%		1.44	%
Expected life (years)		7.00			7.00
Expected share price volatility		155	%		166	%
Expected dividend yield		0	%		0	%

Warrants Granted [Member]

Class of Warrant or Right [Line Items]

Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]

The fair value of placement agent warrants granted was determined using the Black-Scholes option valuation model, using the following weighted average assumptions at the date of the grant:

	Year Ended
	September 30,
	2018
Risk free interest rate		2.21	%
Expected life (years)		5.0
Expected share price volatility		173	%
Expected dividend yield		0	%

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Income Taxes (Tables)

12 Months Ended

Sep. 30, 2018

Income Tax Disclosure [Abstract]

Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]

The breakdown of loss before income tax by jurisdiction is as follows:

	Years Ended
	September 30,			September 30,
	2018			2017

U.S.	$	(4,306,650	)	$	(4,540,094	)
Canadian		(623,835	)		(464,990	)
Other foreign		(107,664	)		(24,764	)

Total Loss Before Income Tax	$	(5,038,149	)	$	(5,029,848	)

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

Deferred income tax assets and liabilities of the Company are as follows:

	September 30, 2018			September 30, 2017

Deferred income tax assets:
Non-capital loss carry-forwards	$	10,646,900		$	12,164,100
Research and development tax credits		1,117,100			947,300
Deferred expenses		36,400			34,300
Property, plant and equipment		-			2,200
Share issuance costs		981,800			142,600
Deferred income tax liabilities:
U.S. federal benefit (liability) of state deferred taxes		(666,700	)		(923,700	)
Property, plant and equipment		(1,800	)		-
Valuation allowance		(12,113,700	)		(12,366,800	)

Net deferred income tax asset (liability)	$	-		$	-

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

	Years Ende d
	September 30, 2018			September 30, 2017

Combined Canadian federal and provincial tax rates		27.0	%		26.0	%

Expected income tax (recovery)/expense	$	(1,360,300	)	$	(1,307,800	)

Nondeductible share-based payments		41,700			30,000
Deductible share issuance costs		(287,300	)		(66,300	)
Effect of income tax rate differences in the U.S. and Mexico		(33,500	)		(624,400	)
Impact of tax rate changes		2,906,100			-
Foreign currency differences		9,500			(42,200	)
Other		(143,100	)		(108,200	)
Change in valuation allowance on deferred tax assets		(1,132,300	)		2,119,700

Income tax expense	$	800		$	800

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

The components of income tax provision (benefits) are as follows:

	Years Ended
	September 30, 2018			September 30, 2017

Current tax provision
U.S. federal	$	-		$	-
Canadian		-			-
Other foreign		-			-
State		800			800

Deferred tax provision
U.S. federal		2,059,300			(1,447,100	)
Canadian		(446,700	)		(199,100	)
Other foreign		(22,600	)		(5,200	)
State		(457,700	)		(468,300	)

Change in valuation allowance on deferred tax assets		(1,132,300	)		2,119,700

Total	$	800		$	800

Fair Value of Financial Instruments (Tables)

12 Months Ended

Sep. 30, 2018

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

The following table summarizes fair values for those assets and liabilities with fair value measured on a recurring basis.

	Fair Value Measurements Using
	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Fair Value

September 30, 2018
Assets
Short-term investments in U.S. Treasury Bills	$	6,078,031	$	-	$	-	$	6,078,031

September 30, 2017
Assets
Short-term investments in U.S. Treasury Bills	$	1,994,401	$	-	$	-	$	1,994,401

Concentrations of Credit Risk (Tables)

12 Months Ended

Sep. 30, 2018

Concentrations of Credit Risk [Abstract]

Schedules of Concentration of Risk, by Risk Factor [Table Text Block]

The Company had the following concentrations of revenues by customers, each of which accounted for more than 10% of revenues in the applicable period:

	Years Ended
	September 30,		September 30,
	2018		2017
Product sales and contract services revenue		59% from 2 customers		79% from 2 customers

The Company had the following concentrations of revenues by geographic areas:

	Years Ended
	September 30,			September 30,
	2018			2017

Europe		51	%		64	%
North America		45	%		33	%
Asia		4	%		3	%

The Company had the following concentrations of accounts receivable from its customers, each of which accounted for more than 10% in the applicable period:

		September 30,
		2018

Accounts receivable		87% from 2 customers

Nature of Operations (Details Textual) - USD ($)	12 Months Ended
Nature of Operations (Details Textual) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Nature of Operations [Line Items]
Net loss	$ (5,038,949)	$ (5,030,648)
Accumulated deficit	(50,430,992)	$ (45,392,043)
Working capital	$ 10,200,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Significant Accounting Policies (Details Textual)	12 Months Ended
Significant Accounting Policies (Details Textual)	Sep. 30, 2018
Minimum [Member]
Property, Plant and Equipment, Useful Life	1 year 6 months
Maximum [Member]
Property, Plant and Equipment, Useful Life	15 years

Investments (Details) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
U.S. Treasury Bills	$ 6,078,031	$ 1,994,401

Inventory (Details) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Raw materials	$ 46,670	$ 21,761
Work in process	83,297	0
Finished goods	94,300	46,353
Inventory	$ 224,267	$ 68,114

Property, Plant and Equipment, net (Details) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	$ 1,782,496	$ 1,703,623
Less: accumulated depreciation	(1,146,566)	(969,418)
Depreciable assets, net	635,930	734,205
Construction in progress	426,265	145,318
Property, plant and equipment, net	1,062,195	879,523
Aquaculture system [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	126,257	126,257
Laboratory facilities [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	62,033	62,033
Computer and office equipment [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	125,859	117,840
Manufacturing And Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	1,042,993	982,439
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	77,994	77,994
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	$ 347,360	$ 337,060

Property, Plant and Equipment, net (Details Textual) - USD ($)	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 188,000	$ 179,000

Commitments (Details)	Sep. 30, 2018 USD ($)
For The Year Ending September 30,
2019	$ 185,000
2020	167,000
2021	6,000
Future minimum lease payments, Total	$ 358,000

Commitments (Details Textual)	12 Months Ended
Commitments (Details Textual)	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2016 EUR (€)	Aug. 14, 2002 USD ($)
Other Commitments [Line Items]
Lessee, Operating Lease, Term of Contract	5 years
Rent expense on lease agreements	$ 237,000	$ 238,000
Equity Method Investments	46,456	66,695
Joint venture agreement [Member]
Other Commitments [Line Items]
Equity Method Investments Committed Capital \| €				€ 120,000
Equity Method Investment, Ownership Percentage			30.00%	30.00%
Equity Method Investments			$ 67,000
Director and Officer [Member] \| Royalty Agreements [Member]
Other Commitments [Line Items]
Royalty percentage of gross receipts over base amount					5.00%
Gross receipt base amount for royalty calculation					$ 500,000
Royalty expense	0	0
401(k) Retirement Savings Plan [Member]
Other Commitments [Line Items]
Employer contributions	$ 75,000	$ 62,000
Employee vesting percentage	100.00%
Annual non-elective safe harbor employer contribution	3.00%
Agreements With Contract Manufacturing Organizations And Consultants [Member]
Other Commitments [Line Items]
Purchase obligations	$ 201,000
Three buildings and facilities used in its operations [Member]
Other Commitments [Line Items]
Lessee, Operating Lease, Renewal Term	5 years
Facilities used for executive offices and laboratories [Member]
Other Commitments [Line Items]
Lessee, Operating Lease, Renewal Term	2 years
Undeveloped land in Baja, Mexico
Other Commitments [Line Items]
Lessee, Operating Lease, Renewal Term	3 years

Share Capital (Details) - USD ($)	12 Months Ended
Share Capital (Details) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Issuance of common shares	$ 5,493,130
Issuance of common shares upon exercise of warrants	4,650,659	$ 0
Share issuance costs	(1,371,621)
Fair value of placement agent warrants	$ (470,912)	$ 0
Share Capital [Member]
Number of common shares issued	3,827,845	54,834
Issuance of common shares	$ 5,493,130	$ 0
Issuance of common shares upon exercise of warrants	4,650,659	0
Issuance of performance shares	0	$ 1,070,909
Share issuance costs	(1,371,621)
Fair value of placement agent warrants	$ (470,912)

Share Capital (Details 1)	12 Months Ended
Share Capital (Details 1)	Sep. 30, 2018 $ / shares shares
Number of Warrants, Ending Balance	4,093,960
Warrant [Member]
Number of Warrants, Beginning Balance	180,805
Number of Warrants, Granted	5,665,528
Number of Warrants, Granted pre-funded warrants	687,076
Number of Warrants, Exercised	(1,752,373)
Number of Warrants, Exercised pre-funded warrants	(687,076)
Number of Warrants, Ending Balance	4,093,960
Weighted Average Exercise Price, Beginning Balance \| $ / shares	$ 31.50
Weighted Average Exercise Price, Granted \| $ / shares	2.68
Weighted Average Exercise Price, Granted pre-funded warrants \| $ / shares	0.01
Weighted Average Exercise Price, Exercised \| $ / shares	2.65
Weighted Average Exercise Price, Exercised pre-funded warrants \| $ / shares	0.01
Weighted Average Exercise Price, Ending Balance \| $ / shares	$ 3.96

Share Capital (Details 2)	12 Months Ended
Share Capital (Details 2)	Sep. 30, 2018 $ / shares shares
Number of Warrants	4,093,960
Warrant One [Member]
Exercise Price \| $ / shares	$ 2.65
Number of Warrants	2,044,152
Expiry Date	Dec. 31, 2018
Warrant Two [Member]
Exercise Price \| $ / shares	$ 31.50
Number of Warrants	180,805
Expiry Date	Jan. 31, 2022
Warrant Three [Member]
Exercise Price \| $ / shares	$ 2.65
Number of Warrants	1,645,175
Expiry Date	May 31, 2023
Warrant Four [Member]
Exercise Price \| $ / shares	$ 3.31
Number of Warrants	223,828
Expiry Date	May 31, 2023

Share Capital (Details 3) - Warrants Granted [Member]	12 Months Ended
Share Capital (Details 3) - Warrants Granted [Member]	Sep. 30, 2018
Risk free interest rate [Member]
Fair Value assumptions rate	2.21%
Expected life (years) [Member]
Expected life (years)	5 years
Expected share price volatility [Member]
Fair Value assumptions rate	173.00%
Expected dividend yield [Member]
Fair Value assumptions rate	0.00%

Share Capital (Details 4)	12 Months Ended
Share Capital (Details 4)	Sep. 30, 2018 $ / shares shares	Sep. 30, 2018 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Beginning Balance \| shares	58,711	58,711
Number of Options, Granted \| shares	29,426	29,426
Number of Options, Expired \| shares	(2,266)	(2,266)
Number of Options, Expired \| shares	(15,373)	(15,373)
Number of Options, Ending Balance \| shares	70,498	70,498
Weighted Average Exercise Price, Beginning Balance \| $ / shares	$ 40.18
Weighted Average Exercise Price, Granted \| $ / shares	5.88
Weighted Average Exercise Price, Expired \| $ / shares	84.87
Weighted Average Exercise Price, Expired \| $ / shares		$ 42.07
Weighted Average Exercise Price, Ending Balance \| $ / shares	$ 25.42

Share Capital (Details 5)	12 Months Ended
Share Capital (Details 5)	Sep. 30, 2018 $ / shares shares	Sep. 30, 2018 $ / shares shares	Sep. 30, 2017 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	70,498	70,498	58,711
Exercisable at September 30, 2018	47,778	47,778
Stock Option One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	13,479	13,479
Exercisable at September 30, 2018	13,479	13,479
Range of exercise prices, Lower Range Limit \| $ / shares		$ 15.00
Range of exercise prices, Upper Range Limit \| $ / shares		$ 35.00
Expiry Dates, Start	2019-04	2019-04
Expiry Dates, End	2019-12	2019-12
Stock Option Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	40,046	40,046
Exercisable at September 30, 2018	17,326	17,326
Range of exercise prices, Lower Range Limit \| $ / shares	$ 5.00
Range of exercise prices, Upper Range Limit \| $ / shares	$ 20.00
Expiry Dates, Start	2023-09	2023-09
Expiry Dates, End	2025-03	2025-03
Stock Option Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	7,571	7,571
Exercisable at September 30, 2018	7,571	7,571
Range of exercise prices, Lower Range Limit \| $ / shares		$ 40.00
Range of exercise prices, Upper Range Limit \| $ / shares		$ 70.00
Expiry Dates, Start	2020-05	2020-05
Expiry Dates, End	2022-06	2022-06
Stock Option Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	2,114	2,114
Exercisable at September 30, 2018	2,114	2,114
Range of exercise prices, Lower Range Limit \| $ / shares	$ 50.00
Range of exercise prices, Upper Range Limit \| $ / shares	$ 60.00
Expiry Dates	2022-12	2022-12
Stock Option Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	3,073	3,073
Exercisable at September 30, 2018	3,073	3,073
Range of exercise prices, Lower Range Limit \| $ / shares		$ 105.00
Range of exercise prices, Upper Range Limit \| $ / shares		$ 140.00
Expiry Dates, Start	2018-11	2018-11
Expiry Dates, End	2021-11	2021-11
Stock Option Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	4,215	4,215
Exercisable at September 30, 2018	4,215	4,215
Range of exercise prices, Lower Range Limit \| $ / shares	$ 120.00
Range of exercise prices, Upper Range Limit \| $ / shares	$ 130.00
Expiry Dates	2020-11	2020-11

Share Capital (Details 6) - Employee Stock Option [Member]	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Risk free interest rate [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair Value assumptions rate	2.13%	1.44%
Expected life (years) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (years)	7 years	7 years
Expected share price volatility [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair Value assumptions rate	155.00%	166.00%
Expected dividend yield [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair Value assumptions rate	0.00%	0.00%

Share Capital (Details Textual) - USD ($)		1 Months Ended	12 Months Ended
Share Capital (Details Textual) - USD ($)	May 15, 2018	May 24, 2018	Sep. 30, 2018	Sep. 30, 2017
Share Capital [Line Items]
Weighted average contractual life remaining on the outstanding warrants			28 months
Weighted average fair value of share options awarded			$ 5.67	$ 12.88
Unrecognized share-based compensation expense			$ 72,000
Unrecognized share-based compensation expense, recognition period			28 months
Share Price	$ 2.65
Proceeds from Issuance Initial Public Offering	$ 4,600,000
Stock Issued During Period, Shares, Conversion of Units	145,283
Number Of Units Issued Through Public Offering	1,388,396
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,122,076
Proceeds from Issuance of Warrants		$ 2,500,000
Investment Warrants, Exercise Price	$ 3.3125
Stockholders' Equity Note, Stock Split			As a result of the reverse split, every seven shares of the issued and outstanding common shares, without par value, consolidated into one newly-issued outstanding common share, without par value. Each fractional share remaining after the reverse split that was less than one-half of a share was cancelled and each fractional share that was at least one-half of a share was changed to one whole share. The reverse split reduced the number of common shares outstanding from 10,520,096 to 1,502,870 after fractional share rounding.<table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
Common Stock, Capital Shares Reserved for Future Issuance			142,857
Number Of Pre funded Units Issued Through Public Offering	687,076
Public Offering Description	The registered public offering also included 687,076 pre-funded units, offered to certain purchasers in lieu of units that would otherwise result in such purchaser’s beneficial ownership exceeding 4.99% (or at the election of a purchaser, 9.99%) of outstanding common shares.
Weighted Average Exercise Price Of Each Pre Funded Warrants	$ 0.01
Weighted Average Exercise Price Of Pre Funded Unit Common Share	$ 0.01
Warrants Granted [Member]
Share Capital [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 1.98
Warrant Three [Member]
Share Capital [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 2.65
Private Placement [Member]
Share Capital [Line Items]
Stock Issued During Period, Shares, Conversion of Units		78,545
Investment Warrants, Exercise Price		$ 3.3125
Series A Common Stock [Member]
Share Capital [Line Items]
Share Price		$ 2.65
Stock Issued During Period, Shares, Conversion of Units		1,122,076
Series B Common Stock [Member]
Share Capital [Line Items]
Share Price		$ 2.65
Stock Issued During Period, Shares, Conversion of Units		2,244,152
Employee Share Option [Member]
Share Capital [Line Items]
Share based compensation, shares reserved for issuance			228,143
Share based compensation, share option vesting schedule			<div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-left: 0.25in;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The exercise price of an option is set at the closing price of the Company’s common shares on the date of grant. Share options granted to directors, officers, employees and certain individual consultants for past service are subject to the following vesting schedule: (a) one-third shall vest immediately, (b) one-third shall vest at 12 months from the date of grant and (c) one-third shall vest at 18 months from the date of grant.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
Employee Stock Option One [Member]
Share Capital [Line Items]
Share based compensation, share option vesting schedule			<div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-left: 0.25in;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Share options granted to directors, officers, employees and certain individual consultants for future service are subject to the following vesting schedule: (x) one-third shall vest at 12 months from the date of grant, (y) one-third shall vest at 24 months from the date of grant and (z) one-third shall vest at 36 months from the date of grant.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

Income Taxes (Details) - USD ($)	12 Months Ended
Income Taxes (Details) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Income Tax Contingency [Line Items]
U.S.	$ (4,306,650)	$ (4,540,094)
Canadian	(623,835)	(464,990)
Other foreign	(107,664)	(24,764)
Loss Before Income Tax	$ (5,038,149)	$ (5,029,848)

Income Taxes (Details 1) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Deferred income tax assets:
Non-capital loss carry-forwards	$ 10,646,900	$ 12,164,100
Research and development tax credits	1,117,100	947,300
Deferred expenses	36,400	34,300
Property, plant and equipment	0	2,200
Share issuance costs	981,800	142,600
Deferred income tax liabilities:
U.S. federal benefit (liability) of state deferred taxes	(666,700)	(923,700)
Property, plant and equipment	(1,800)	0
Valuation allowance	(12,113,700)	(12,366,800)
Net deferred income tax asset (liability)	$ 0	$ 0

Income Taxes (Details 2) - USD ($)	12 Months Ended
Income Taxes (Details 2) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Income Tax Contingency [Line Items]
Combined Canadian federal and provincial tax rates	27.00%	26.00%
Expected income tax (recovery)/expense	$ (1,360,300)	$ (1,307,800)
Nondeductible share-based payments	41,700	30,000
Deductible share issuance costs	(287,300)	(66,300)
Effect of income tax rate differences in the U.S. and Mexico	(33,500)	(624,400)
Impact of tax rate changes	2,906,100
Foreign currency differences	9,500	(42,200)
Other	(143,100)	(108,200)
Change in valuation allowance on deferred tax assets	(1,132,300)	2,119,700
Income tax expense	$ 800	$ 800

Income Taxes (Details 3) - USD ($)	12 Months Ended
Income Taxes (Details 3) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Current tax provision
U.S. federal	$ 0	$ 0
Canadian	0	0
Other foreign	0	0
State	800	800
Deferred tax provision
U.S. federal	2,059,300	(1,447,100)
Canadian	(446,700)	(199,100)
Other foreign	(22,600)	(5,200)
State	(457,700)	(468,300)
Change in valuation allowance on deferred tax assets	(1,132,300)	2,119,700
Total	$ 800	$ 800

Income Taxes (Details Textual) $ in Millions	9 Months Ended	12 Months Ended
Income Taxes (Details Textual) $ in Millions	Sep. 30, 2018 USD ($)	Sep. 30, 2018 USD ($)	Dec. 31, 2017	Sep. 30, 2017 USD ($)	Sep. 30, 2018 CAD ($)
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		27.00%		26.00%
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount		$ 1,132,300		$ (2,119,700)
Domestic Tax Authority [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%		35.00%
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount		2,950,000
Foreign Tax Authority [Member]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount		40,000
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent	12.00%		11.00%
Federal [Member]
Operating Loss Carryforwards	$ 29,600,000	$ 29,600,000
Federal [Member] \| Earliest Tax Year [Member]
Operating Loss Carryforwards, Expiration Date		Dec. 31, 2030
Federal [Member] \| Latest Tax Year [Member]
Operating Loss Carryforwards, Expiration Date		Dec. 31, 2038
Federal [Member] \| Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	530,000	$ 530,000
Federal [Member] \| Research Tax Credit Carryforward [Member] \| Earliest Tax Year [Member]
Operating Loss Carryforwards, Expiration Date		Dec. 31, 2030
Federal [Member] \| Research Tax Credit Carryforward [Member] \| Latest Tax Year [Member]
Operating Loss Carryforwards, Expiration Date		Dec. 31, 2038
California [Member]
Operating Loss Carryforwards	29,200,000	$ 29,200,000
California [Member] \| Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	$ 580,000	$ 580,000
Canadian [Member]
Operating Loss Carryforwards					$ 8.7
Canadian [Member] \| Latest Tax Year [Member]
Operating Loss Carryforwards, Expiration Date		Dec. 31, 2038

Fair Value of Financial Instruments (Details) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments in U.S. Treasury Bills	$ 6,078,031	$ 1,994,401
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments in U.S. Treasury Bills	6,078,031	1,994,401
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments in U.S. Treasury Bills	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments in U.S. Treasury Bills	$ 0	$ 0

Concentrations of Credit Risk (Details)	12 Months Ended
Concentrations of Credit Risk (Details)	Sep. 30, 2018	Sep. 30, 2017
Customer Concentration Risk [Member] \| Product sales and contract services revenue [Member] \| Two Customers [Member]
Concentration Risk [Line Items]
Concentration risk percentage	59.00%	79.00%
Customer Concentration Risk [Member] \| Accounts receivable [Member] \| Two Customers [Member]
Concentration Risk [Line Items]
Concentration risk percentage	87.00%
Geographic Concentration Risk [Member] \| Revenue [Member] \| Europe [Member]
Concentration Risk [Line Items]
Concentration risk percentage	51.00%	64.00%
Geographic Concentration Risk [Member] \| Revenue [Member] \| North America [Member]
Concentration Risk [Line Items]
Concentration risk percentage	45.00%	33.00%
Geographic Concentration Risk [Member] \| Revenue [Member] \| Asia [Member]
Concentration Risk [Line Items]
Concentration risk percentage	4.00%	3.00%